HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Sublingual Lesson Surfaces Again In Dietary Supplement Warning

This article was originally published in The Rose Sheet

Executive Summary

The latest firm to hear from FDA that sublingual tablets are not supplements is Bio-Stasis International, according to a warning letter from the Office of Regulatory Affairs' Los Angeles District.

You may also be interested in...



Spray Supplement Zinc Up Developed On Idea Of Providing Immunity ‘Barrier’ For First Responders

"We were seeing how important immune support is and that’s kind of the origination of the idea," says Nutritional Brands CEO Danna Pratte. "It really was sparked because of the conversation about first responders and their need for protection."

FDA Liquid Supplement/Beverage Guidance Defines Distinctions

The CFSAN guidance goes into greater detail on distinguishing liquid supplements from beverages, addressing stakeholders’ complaint about a 2009 draft. “This tends to really draw a bright line between the two different categories,” says CRN Regulatory Counsel Rend Al-Mondhiry.

In Brief: warning letters, UrgentRx OTCs fly, Innovus acquires Semprae

GMPs apply despite product discontinuation; format renders spray products drugs; Rogaine label clarified; UrgentRx OTCs take flight; Innovus acquires Semprae; Omega Protein closes plant; FDA evaluates consumer communication; and EU vitamin, mineral, botanical sales outpace forecast.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel